STAT June 18, 2021
Dan Troy

Right now, more than 100,000 Americans are waiting for organ transplants. Due to a lack of available kidneys, livers, hearts, and lungs, at least 17 of them die each day.

Using 3D bioprinting to create new organs — and personalize them for recipients — could prevent these tragic deaths. Yet inaction at the Food and Drug Administration is impeding the rollout of this technology. Regulators have not yet come up with a framework for reviewing and approving these lab-grown organs. Until they do, Americans awaiting organ transplants will continue to suffer.

These people already face long odds. A willing donor must die or, in the case of kidney transplants, a living donor must agree to a major procedure. Donors’ organs...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: 3D Printing, FDA, Govt Agencies, Provider, Technology
Technologies Transforming the Surgical Experience
WASP Highlights Advances in Healthcare 3D Printing at Italy’s Exposanità 2024
3D Systems Brings 3D Printed PEEK Cranial Implant to the U.S. with FDA Clearance
3D Printing Market Hits $14.7B Amid Challenges in 2023
World’s First Bioprinted Trachea Transplant Marks a New Era in Medical Innovation

Share This Article